Gastrointestinal Stromal Tumor

• 
  

  Limited Resection in Duodenal GIST Eliminated Local Recurrence

  RESEARCH REPORT
  Leah Lawrence
  Limited surgical resection of duodenal gastrointestinal stromal tumors resulted in positive outcomes for both local and systemic disease-free survival, according to the results of a small study.

• 
  

  Long-Term Treatment With Imatinib Affected Bone Mineral Density

  RESEARCH REPORT
  Leah Lawrence
  A majority of patients on imatinib for treatment of GIST or CML had low or absent levels of osteocalcin, a bone marker secreted by osteoblasts, and about 50% of patients had a decrease in bone mineral density, signaling that long-term treatment may affect bone health in these patients.

• 

  58-Year-Old Male Presents With Stomach Mass

  TEST YOUR IMAGE IQ
  Robert D. Cardiff, MD, PhD
  A 58-year-old male presents with chief complaints of bloating, vague abdominal pain, and dark black stools. He is referred to a gastroenterologist who recommends upper and lower endoscopy. What is the most likely diagnosis?

• 
  

  Targeted Therapy: Its Status and Promise Part I

  REVIEW ARTICLE ONCOLOGY Vol. 26 No. 10
  We describe areas where major inroads were initially achieved by targeting angiogenesis and by unraveling pathways in the heterogeneous tumors of mesenchymal origin—spurred by the identification of c-Kit–activating mutations in GIST and the regressions that ensued when tumors harboring these mutations were exposed to the tyrosine kinase inhibitor imatinib (Gleevec).

  • Improving Harmonious Precision • Asking the Right Questions
• 
  

  Perioperative Treatment of GIST

  REVIEW ARTICLE ONCOLOGY Vol. 23 No. 1
  This review describes the current multidisciplinary management of gastrointestinal stromal tumor (GIST), which is the most common sarcoma of the gastrointestinal tract. Before 2001, surgery was the only effective therapy for GIST.

  • Perioperative Tyrosine Kinase Inhibitors for GIST: Further Investigation?
  • Controversies in the Surgical Management of GIST in the Era of Imatinib